ClinicalTrials.gg
CompletedNCT00184795CHOICEUpdated Feb 23, 2017

Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations

A Phase 3 interventional study of 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) and 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) in Menopause and Menopausal Vasomotor Symptoms, sponsored by Novo Nordisk A/S. Completed at 92 sites in 10 countries. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled May 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
576
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.

Enrollment
5th of 13
576 · median 431
Started
2004
with 2 others
Phase 3
8 of 13
none open now
Registered
3rd of 13
by date
Lead sponsor
1 of 13
Novo Nordisk A/S

Among the 13 studies testing estradiol in Hot Flashes, this one is the 5th largest by enrollment, is one of 3 that started in 2004, is one of 8 in phase 3, and was the 3rd registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About estradiol

Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 45 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing estradiol in Hot Flashes as a file.
02

Study summary

This trial is conducted in Europe. Postmenopausal women with moderate to severe hot flashes have been recruited into the trial. The earliest effect of ultra low dose HRT (hormone replacement therapy) on frequency and severity of menopausal symptoms, bleeding patterns and safety of different hormonal combinations will be evaluated and compared to placebo over the six month treatment period.

03

Conditions studied

  • Menopause
  • Menopausal Vasomotor Symptoms

Browse trials for

Keywords

  • Hot flashes
04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • status
  • Subject should have had a minimum of 7 moderate to severe hot flushes per day, or a minimum of 50 moderate to severe hot flushes per week, during the last 2 weeks of the run-in (screening) period.
  • Subject with an intact uterus

Exclusion criteria

Exclusion Criteria:

  • In accordance with existing labelling for estrogen/progestogen combinations
  • (BMI) > 35.0 kg/m2
  • Known alcohol or drug abuse, heavy smoking (more than 20 cigarettes a day)
  • Currently using hormones (except topical or inhalation glucocorticoid preparations) and drugs known to influence estrogen metabolism such as barbiturates, phenytoin, rifampicin, carbamazepin
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
576 participants (actual)

Study arms

  • Experimental
    ALD 0.1

    Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)

  • Experimental
    ALD 0.25

    Drug: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • Drug0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)

    Drug pages: Estradiol · Norethindrone Acetate

    One tablet per day for 24 weeks

  • Drug0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)

    Drug pages: Estradiol · Norethindrone Acetate

    One tablet per day for 24 weeks

  • Drugplacebo

    Placebo tablets for 24 weeks

06

What researchers measure

Primary outcomes

  1. Change in mean number of moderate to severe hot flushes per week

    Time frame: At week 8

Secondary outcomes

  1. Urogenital symptoms

    Time frame: Week 0; week 24

  2. Vaginal cytology and pH

    Time frame: Week 0; week 24

  3. Bleeding profile

    Time frame: Week 0; week 24

  4. Adverse Events

    Time frame: Week 0; week 24

  5. Menopausal symptoms and quality of life (Greene Climacteric Scale)

    Time frame: Week 0; week 24

  6. Hot flush weekly weighted score

    Time frame: Week 0; week 24

07

Study locations

92 sites
  • Novo Nordisk Investigational Site
    Wien, A 1060, Austria
  • Novo Nordisk Investigational Site
    Wien, A 1090, Austria
  • Novo Nordisk Investigational Site
    Brussels, 1000, Belgium
  • Novo Nordisk Investigational Site
    Brussels, 1200, Belgium
  • Novo Nordisk Investigational Site
    Bruxelles, 1180, Belgium
  • Novo Nordisk Investigational Site
    Gent, 9000, Belgium
  • Novo Nordisk Investigational Site
    Huy, 4500, Belgium
  • Novo Nordisk Investigational Site
    Leuven, 3000, Belgium
  • Novo Nordisk Investigational Site
    Liège, 4000, Belgium
  • Novo Nordisk Investigational Site
    Montigny-Le-Tilleul, 6110, Belgium
  • Novo Nordisk Investigational Site
    Watermael-Boifort, 1170, Belgium
  • Novo Nordisk Investigational Site
    Allerød, 3450, Denmark
  • Novo Nordisk Investigational Site
    Frederiksberg, 2000, Denmark
  • Novo Nordisk Investigational Site
    Hvidovre, 2650, Denmark
  • Novo Nordisk Investigational Site
    København N, 2400, Denmark
  • Novo Nordisk Investigational Site
    Næstved, 4700, Denmark
  • Novo Nordisk Investigational Site
    Odense C, 5000, Denmark
  • Novo Nordisk Investigational Site
    Virum, 2830, Denmark
  • Novo Nordisk Investigational Site
    Århus C, 8000, Denmark
  • Novo Nordisk Investigational Site
    Espoo, 02200, Finland
  • Novo Nordisk Investigational Site
    Helsinki, 00100, Finland
  • Novo Nordisk Investigational Site
    Oulu, 90100, Finland
  • Novo Nordisk Investigational Site
    Tampere, 33101, Finland
  • Novo Nordisk Investigational Site
    Turku, 20100, Finland
  • Novo Nordisk Investigational Site
    Amiens, France
  • Novo Nordisk Investigational Site
    LA ROCHE-sur-YON cedex 9, 85295, France
  • Novo Nordisk Investigational Site
    MARSEILLE cedex 05, 13385, France
  • Novo Nordisk Investigational Site
    Marseille, 13004, France
  • Novo Nordisk Investigational Site
    MONTPELLIER cedex 05, 34295, France
  • Novo Nordisk Investigational Site
    Montpellier, 34000, France
  • Novo Nordisk Investigational Site
    NANTES cedex 1, 44093, France
  • Novo Nordisk Investigational Site
    Narbonne, 11108, France
  • Novo Nordisk Investigational Site
    Nice, 06000, France
  • Novo Nordisk Investigational Site
    NIMES cedex 9, 30000, France
  • Novo Nordisk Investigational Site
    Nimes, 30000, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex 9, 31059, France
  • Novo Nordisk Investigational Site
    Jessen, 06917, Germany
  • Novo Nordisk Investigational Site
    Karlsruhe, 76199, Germany
  • Novo Nordisk Investigational Site
    Leipzig, 04207, Germany
  • Novo Nordisk Investigational Site
    Lorsch, 64653, Germany
  • Novo Nordisk Investigational Site
    Rheine, 48431, Germany
  • Novo Nordisk Investigational Site
    Rheinstetten, 76287, Germany
  • Novo Nordisk Investigational Site
    Schorndorf, 73614, Germany
  • Novo Nordisk Investigational Site
    Stuttgart, 70563, Germany
  • Novo Nordisk Investigational Site
    Tübingen, 72076, Germany
  • Novo Nordisk Investigational Site
    Völklingen, 66333, Germany
  • Novo Nordisk Investigational Site
    Grålum, 1713, Norway
  • Novo Nordisk Investigational Site
    Hamar, NO-2317, Norway
  • Novo Nordisk Investigational Site
    Kolbotn, 1410, Norway
  • Novo Nordisk Investigational Site
    Lillestrøm, 2000, Norway
  • Novo Nordisk Investigational Site
    Oslo, 0309, Norway
  • Novo Nordisk Investigational Site
    Paradis, 5231, Norway
  • Novo Nordisk Investigational Site
    Stavanger, 4088, Norway
  • Novo Nordisk Investigational Site
    Stavanger, NO-4011, Norway
  • Novo Nordisk Investigational Site
    Trondheim, NO-7012, Norway
  • Novo Nordisk Investigational Site
    Göteborg, 411 19, Sweden
  • Novo Nordisk Investigational Site
    Göteborg, 416 85, Sweden
  • Novo Nordisk Investigational Site
    Linköping, 581 85, Sweden
  • Novo Nordisk Investigational Site
    Linköping, 582 22, Sweden
  • Novo Nordisk Investigational Site
    Lund, 221 85, Sweden
  • Novo Nordisk Investigational Site
    Malmö, 217 44, Sweden
  • Novo Nordisk Investigational Site
    Norrköping, 602 32, Sweden
  • Novo Nordisk Investigational Site
    Uppsala, 751 85, Sweden
  • Novo Nordisk Investigational Site
    Bulle, 1630, Switzerland
  • Novo Nordisk Investigational Site
    Frauenfeld, 8500, Switzerland
  • Novo Nordisk Investigational Site
    Weinfelden, 8570, Switzerland
  • Novo Nordisk Investigational Site
    Zürich, 8032, Switzerland
  • Novo Nordisk Investigational Site
    Zürich, 8091, Switzerland
  • Novo Nordisk Investigational Site
    Aldershot, GU12 5BA, United Kingdom
  • Novo Nordisk Investigational Site
    Bexhill-on-Sea, TN39 4SP, United Kingdom
  • Novo Nordisk Investigational Site
    Birmingham, BE9'1 2JL, United Kingdom
  • Novo Nordisk Investigational Site
    Bolton, BL1 6AF, United Kingdom
  • Novo Nordisk Investigational Site
    Chesterfield, Derbyshire, S40 4AA, United Kingdom
  • Novo Nordisk Investigational Site
    Chippenham, SN15 1HP, United Kingdom
  • Novo Nordisk Investigational Site
    Cornwell, TR1 2LZ, United Kingdom
  • Novo Nordisk Investigational Site
    Coventry, CV6 2FL, United Kingdom
  • Novo Nordisk Investigational Site
    Devon, BH15 2JB, United Kingdom
  • Novo Nordisk Investigational Site
    Hastings, TN34 3EY, United Kingdom
  • Novo Nordisk Investigational Site
    Hull, HU2 8PX, United Kingdom
  • Novo Nordisk Investigational Site
    Linclolshire, PE21 6PF, United Kingdom
  • Novo Nordisk Investigational Site
    Liverpool, L8 7SS, United Kingdom
  • Novo Nordisk Investigational Site
    London, SE1 9RT, United Kingdom
  • Novo Nordisk Investigational Site
    London, SE5 8RS, United Kingdom
  • Novo Nordisk Investigational Site
    London, W12 0HS, United Kingdom
  • Novo Nordisk Investigational Site
    Manchester, M13 0JH, United Kingdom
  • Novo Nordisk Investigational Site
    Norfolk, NR4 7UZ, United Kingdom
  • Novo Nordisk Investigational Site
    Oxford, OX3 9UD, United Kingdom
  • Novo Nordisk Investigational Site
    Reading, RG7 3SQ, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S1 2PJ, United Kingdom
  • Novo Nordisk Investigational Site
    Stoke on Trent, ST4 6QG, United Kingdom
  • Novo Nordisk Investigational Site
    Suffolk, IP33 1HE, United Kingdom
  • Novo Nordisk Investigational Site
    WAtford, HA1 3UJ, United Kingdom
08

References and documents

Publications

  • Sturdee DW, Archer DF, Rakov V, Lang E; CHOICE Study Investigators. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric. 2008 Feb;11(1):63-73. doi: 10.1080/13697130701852390. PubMed 18202966 ↗
  • Lundstrom E, Bygdeson M, Svane G, Azavedo E, von Schoultz B. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric. 2007 Jun;10(3):249-56. doi: 10.1080/13697130701385805. PubMed 17487652 ↗
  • Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007 Apr;10(2):120-31. doi: 10.1080/13697130701298107. PubMed 17453860 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2004 to primary completion in May 2005, 11 months.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 16, 2005
StartActual
May 28, 2004
Primary completionActual
May 4, 2005
CompletionActual
May 4, 2005
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00184795
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 16, 2005
Start date
May 28, 2004
Primary completion
May 4, 2005
Completion
May 4, 2005
Last update
Feb 23, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Norethindrone Acetate

Start the discussion